Medizone Home
×

Meet Us At Our Booth At ARAB HEALTH 2020 – 27 to 30 January

We are looking forward to welcoming you at our booth at ARAB HEALTH –

Maktoum Hall – Booth Number M.D33

27th to 30th January 2020.

For more information visit ARAB HEALTH exhibitor directory.

 

Meet us at CPHI in Frankfurt

We will attend the CHPI in Frankfurt – you can meet our MD – please contact us to fix the dates.

More information on the CHPI

 

Thanks for visiting us at Expopharm 2019

Thank you for visiting us at Expopharm in Munich this year!

It was a great pleasure to have the opportunity again to speak in person with many of our business partners.

Meet us at Expopharm 2019 – Düsseldorf 25th to 28th September

We will have a booth again this year at expopharm Düsseldorf and hope that we can welcome you again in Hall 3 / Booth D32

For more information visit expopharm exhibitor director

„Wings for Life“ honors Medizone for continues support!

Wings for Life – Spinal Cord Research Foundation

Worldwide, millions of people are dependent on a wheelchair after having sustained a spinal cord injury, most often as the result of a traffic accident or a fall. Wings for Life is a not-for-profit spinal cord research foundation with the single mission to find the cure for spinal cord injury. Since 2004, Wings for Life has funded life-changing research projects and clinical trials around the globe. While the cure is still to be found, steady progress has been made. One hundred percent of donations will help work toward Wings for Life’s ultimate goal.

www.wingsforlife.com

„It can happen to anyone of us. The question is not whether effective treatments and cures will be found, but when they will be found! We are proud to support Wings for Life!“

Gerhard Hoerl / MD Medizone Germany GmbH

Spinal cord injury must become curable!

Meet us at Clinical Operations in Oncology Trial Europe 2018

Meet us at our Booth at Clinical Operations in Oncology Trial Europe 2018
at the Hilton Munich Airport from 14 – 15 November 2018.

We look forward to meeting you there!

Thanks for visiting us at Expopharm 2018!

Thank you for visiting us at Expopharm in Munich this year. It was a great pleasure to have the opportunity again to speak in person with many of our business partners.

One big subject was the safety of drugs which is always our number one priority. Therefore, long-term trusting business partnerships are of great importance to us.

Meet Us At Our Booth At ARAB HEALTH 2019 – 28 to 31 January

We are looking forward to welcoming you at our booth at ARAB HEALTH –

Stand No. (Za’abeel Hall 3)  Z3 / E.40.

28th to 31st January 2019.

For more information visit ARAB HEALTH exhibitor directory.

Meet us at Expopharm 2018 – Munich 10th to 13th October

We will have a booth again this year at expopharm Munich and hope that we can welcome you again in Hall B6 / Booth D17

 

 

 

For more information visit expopharm exhibitor director

CHMP approves pegfilgrastim biosimilar, Pelgraz from Accord/Intas

Pelgraz – a pegylated G-CSF biosimilar, is latest addition to Accord Healthcare’s established portfolio of over 30 oncology treatments across Europe.

Following marketing authorisation Accord Healthcare will potentially be the first to launch pegfilgrastim across Europe.

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Accord’s Pelgraz (pegfilgrastim), pegylated granulocyte-colony stimulating factor (G-CSF) biosimilar in Europe. Once approved, Pelgraz could be the first pegfilgrastim biosimilar to market in Europe indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy. The World Health Organisation consider G-CSF essential therapies due to their impact on febrile neutropenia, chemotherapy dose delays, and dose density.

Intas / Accord will manufacture Pelgraz in its own state of the art production facility. The company has deep experience with biosimilar medicines and as of 2017 were assessed as having the second highest number of biosimilars in phase III to approval in the world. This reflects the strategy of a long-standing commitment in biopharmaceutical development, research and manufacturing.

The CHMP positive opinion was based on Pelgraz’s substantial clinical development programme, which supported its biosimilarity with Neulasta through a Phase I, randomised, assessor-blinded PK/PD study in healthy volunteers, and a Phase III study of patients with breast cancer (stage IIa, IIb, or IIIa) on TAC (docetaxel, doxorubicin, cyclophosphamide).

Source: Intas Press release

Pages:1234567»